上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 综述 • 上一篇    下一篇

miRNA在急性冠脉综合征中的临床研究进展

曹惠敏，薛晓梅，尤纱纱，何 斌   

  1. 上海交通大学 医学院附属新华医院麻醉与重症医学科，上海 200092
  • 出版日期:2016-08-29 发布日期:2016-08-31
  • 通讯作者: 何 斌，电子信箱：hebinicu@139.com。
  • 作者简介:曹惠敏（1992—），男，硕士生；电子信箱：caohuimin0330@163.com。
  • 基金资助:

    国家自然科学基金（81470390，81270003）；上海市教育委员会高峰高原学科建设计划（20152218）；上海交通大学医工交叉项目（YG2013MS20）；上海交通大学医学院附属新华医院临床研究项目（15LC07）

Clinical research progresses of miRNAs in acute coronary syndrome

CAO Hui-min, XUE Xiao-mei, YOU Sha-sha, HE Bin   

  1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2016-08-29 Published:2016-08-31
  • Supported by:

    National Natural Science Foundation of China, 81470390, 81270003; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152218; Medical Engineering Cross Project of Shanghai Jiao Tong University, YG2013MS20; Funding for Clinical Trial of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 15LC07

PDF (PC)

1502

摘要：

急性冠脉综合征（ACS）的发生率和病死率日趋增高，基因治疗已成为当今临床研究领域的热点，而miRNA是很有临床转化应用前景的一类新型目的基因。在ACS中，心肌特异性的miRNA的表达会有所改变，如miR-1、miR-133、miR-208、miR-499在组织和血液中均有显著变化，因此它们有望成为理想的新型生物学标志物，用于ACS的早期诊断及判断预后。尤其是miR-499和miR-208，几乎仅在心肌中表达，具有高度特异性，应用前景广阔。同时，miRNA也可作为心血管疾病新药物作用靶点以达到治疗的效果；通过过表达或拮抗相关miRNA的表达水平，可缓解病程进展，消除部分症状。该文就miRNA在ACS的临床研究进展进行综述。

关键词: miRNA, 急性冠脉综合征, 心血管疾病, 临床研究

Abstract:

The morbidity and mortality of acute coronary syndrome (ACS) are gradually increasing. Gene therapy has become a hot spot in clinical research and microRNAs (miRNAs) are novel target genes with a promising future in clinical application. For ACS, the expressions of cardiac-specific miRNAs will change in both tissues and blood such as miR-1, miR-133, miR-208, and miR-499, which may be ideal new biomarkers for early diagnosis and predicting the prognosis of ACS. miR-499 and miR-208 are particularly prospective because they only express in myocardium with high specificity. Meanwhile, miRNAs may also serve as targets of new cardiovascular drugs, which can slow down the disease progression and alleviate some symptoms via over-expressions or suppression of expressions of related miRNAs. This article reviews clinical research progresses of microRNAs in ACS.

Key words: microRNA, acute coronary syndrome, cardiovascular disease, clinical research